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Chapter 1: General Introduction
Chapter I is rneant as a general introduction to atherosclerosis and the ensuing coronary
artery disease (CAD). It gives special attention to atherogenesis, lipoprotein metabolism
and nutritional factors. The chapter opens with the presentation of an integrated model
ofatherogenesis with a central role for endothelial activation and dysfunction. The latter
results from exposure ofthe endothelium to the, so called, CAD risk factors. These are
composed of genetic factors, environtnental factors and the thrifty phenotype. The risk
factors initiate in a concefted action a pathophysiological cascade that leads to
atherosclerosis development. The final clinical outcome is CAD, stroke, aneurysm or
peripheral vascular disease (notably intermittent claudication). Activation of the
endothelium causes enhanced leukocyte adhesion, increased coagulation and impaired
fibrinolysis, migratior.r and proliÍèration of smooth muscle cells, irnpaired er.rdothelium
dependent vasorelaxation and increased vascular permeability. All of these processes
are characterised by mutual enhancement. The ensuing atherosclerosis causes
endothelial damage, which in turn initiates endothelial activation, and thereby
contributes to athcrosclerosis progression.
Circulating lipids, notably cholesterol located in low density lipoproteins (LDL),
are important rnodifiable CAD risk factors. LDl-cholesterol lowering is therefbre one
of the main therapeutic targets in both printary aud secondary CAD prevention. High
triglycerides, low concentrations of high density lipoproteins (HDL) and predominance
of small dense LDL are other important lipid risk factors, but their concentrations are in
làct often related. It stresses the importance of understanding the (patho)physiological
basis of lipoprotein interrelationships.
The'Seven Countries Study'indicated that serum cholesterol levels do not fully
explair.r CAD rnorlality. The discrepancy is likely to indicate the importance of nutrition
as one of the majol mediators in CAD developrnent. Nutritional factors, in particular the
dietary fatty acid composition, influence plasma lipoprotein levels, but dietary fatty
acids also mediate some of the key events it.t endothelial dysfunction, such as
coagulation. Micronutrients, especially (pro)vitamins like vitamin E and p-carotene,
lnay protect lipoproteins frorn oxidation. Others, notably vitamin 86, vitamin B12 and
lblic acid, influence circulating levels of l.rornocysteine, which is considered eleterious
to the endothelium.
Chapter 2: Apolipoprotein E analysis
Apolipoprotein E (apo-E) physiology and pathophysiology, tl.re importance of
apolipoprotein E isotyping in diabetes mellitus and atherosclerosis, and the cunent apo-E
isotyping metl.rods are reviewed in chapter 2.1.
Apo-E plays a cer.rtral role in tl.re clearance of lipoprotein remnants by serving as a
ligand for LDL and apo-E receptors. Three common alleles (apo-a2, apo-t3 and apo-ea)
give rise to 6 genotypes. Apo-E3 is the ancestral isofomt, the so-called 'wild type'. Apo-E
polyrrorphism influeuces erum triglycerides, and may account for as much as 12 and 4%o
of the interindividual variance of circulating apo-B ar.rd total cholesterol, respectively.
Establishment of apo-Ez/Er confirms the diagnosis familial dysbetalipoproteinaemia (FD).
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high risk of cAD development), choice of lipid lowering therapy, and several non-
atherosclerotic diseases (e.g. Alzheimer's disease).
Present analyses of apo-E isoforms are based on phenotyping or genotyping. Apo-
E phenotyping exploits differences in isoelectric points. Isoelectric focusing (IEF) uses
gels that contain pH 4-7 ampholy'tes and urea. Serum is directly applied, or prepurified by
delipidation, lipoprotein precipitation or dialysation. IEF is followed by
immunofixation/protein staining. Another approach is electro or diffusion blotting,
followed by protein staining or immunological detection with anti apo-E antibodies and an
enzyme-conjugated second antibody. Apo-E genotyping demonstrates the underlying point
mutations. Analyses of polymerase chain reaction (PCR) products are done by allele
specihc oligonucleotide (ASo) probes, restriction fragment length polymorphism (RILP),
single stranded conformational polymorphism (sscP), the primer-guided nucleotide
incorporation assay, or denaturating gradient gel electrophoresis (DGGE). Detection with
primers that either or not initiate amplification is performed with the amplification
refractory mutation system (ARMS). Detection of rare mutants is important, since most of
those that are presently known cause FD. Selection of a routine method, however, is not
based on analyses of rare mutants and neither phenotyping nor genotyping guarantees their
detection. Combination of techniques may be the first choice for further investigation of
patients with FD when, on the basis of a single technique, the cor.rdition can not be
explained by the apo-E2/E2 isoform. Sequencing provides ultimate proof.
The discussion on discrepancies between the outcomes of phenotyping and
genotyping does not seem settled. It appears that the disparity is caused by: IEF
methods that do not adequately separate posttranslational apo-E variants, storage
artefacts or faint IEF bands. Genotyping is usually less laborious than phenotyping and
is obviously unaffected by posttranslational variants. PCR/RFLP is preferred for routine
applications, since it does t.tot necessitate multiple PCR reactions (as with primer-guided
nucleotide incorporation assays and ARMS), does not require detection by hybridisation
(ASO-probes), allows less stringent experimental conditions (SSCP, DGGE, ARMS),
and provides an internal control (a 38 basepair fragment) that minimises the risk of
misinterpretation caused by faint bands.
In chapter 2.2 we describe the discovery by serendipity of a novel apo-E mutation in a
patient with clinical features of FD. The DNA of this patient was used in a comparison
study of two different apo-E genotyping rnethods. we observed a persisting,
unexplained iscrepancy between the outcomes of both methods: PCR/RILP resulted in
Íhe apo-e2le2 genotype, whereas use of a commercially available kit (based on a
minisequence method) indicated the apo-e2/e3 genotype. we hypothesised that the
observed discrepancy resulted either from an altered restriction site (other than the
common C/T substitutions) or a mutation at the annealing site of one of the primers, as
used in the restriction isotyping method. Sequencing of a PCR product that included the
possibie mutation sites, demonstrated a G-inserlion in codons 95 or 96 lesAAG-
'6GAG-+AAG-GGA-G). The ensuing frameshift resuits in a premature stop codon at
codon 146 (AAG-+TAA), which is located in the receptor binding domain. The
discrepancy between the two apo-E genotyping methods is conceivable, since the G-
insertion causes a mismatch at the 3'end of one of the restriction isotyping primers and




to be located on the apo-€3 allele, since this allele was not amplified with the apo-E
restrictior.r isotyping r.nethod.
Chapter 3: Public health
In chapter 3.1 we tried to find an explar.ration for the high CAD risk of Trinidadians of
East-lndiar.r descent. Trinidadian Indians have a2.3-2.4 fold higher relative risk of CAD
development, compared with their African counterpans. Although they have higher
diabetes mellitus prevalence, higher LDl-cholesterol and triglycerides, and lower HDL-
cholesterol, these risk factors do not explain their excessive CAD mortality. Since both
apo-E2 and apo-Ea are associated with ir.rcreased CAD risk, we investigated the apo-E
genotype distributions and un.rbilical plasrna lipid indices in a consecutive sample of
300 newborns in l'rinidad. The apo-E genotype distributions of l'rinidadian Africans
and Indiar.rs were compared with literature data of populations with sir.r.rilar ethnic
backgror.rnds. We also investigated the association of the apo-E ger.rotypes with plasma
lipid indices of Trinidadian newborns. These results were compared with data from a
group of234 consecutive Curagao newborns.
We found that Trinidadian Africans have higher apo-e2 and apo-ea. and lower
apo-e3 allele Íiequencies as compared with their Indian counterpafts. The apo-li
genotype distribution of Trinidadian Africans resembles to a certain extent that of
counterparts in Curagao and Sudan, but not that of counterparls ir.r Nigeria and the USA.
Trinidadian and Singapore Indians had comparable apo-E, genotype distributions.
Trinidadian term appropriate for gestational age newborns o1- AÍiican and Indian
descent had comparable umbilical plasma lipid indices, except Íbr lower l ipoprotein (a)
[Lp(a)] and 'adaptcd l ipid tetrad index' in newborns of Indian descent. Correlation
analysis between apo-E genotypes and urnbilical lipid indices revealed an apo-B
increasing eÍïect of apo-Ê4 and an apo-B decreasing effèct of apo-e2 in both 'l'rinidadian
and Curagao Africans.
Our data showed that apo-E polymorphism in Trinidadian and Curaqao
ncwborns of African descent exerts similar effects on plasma lipoprotein rretabolism.
'Ihe 
apo-B increasing effect of apo-ra, and tl.re cor.nbination of apo-e2 homozygosity
u'ith FD precipitating factors rnay therefore contribute similarly to their CAD
development. Apo-E polymorphism related CAD risk may especially apply to
Trinidadians of African descent, because of their high apo-e2 and apo-ea allele
Íiequencies, but not to Trinidadian Indians, who have low apo-e2 and apo-ea allele
fi'equencies. Trinidadian Indiar.rs also had lower Lp(a) and adapted lipid tetrad index.
We conclude that the apo-E polymorphisrn and umbilical plasma lipid indices do not
explain the higher CAD incidence of Trinidadian Indians, compared with their African
counterparts.
The study does not provide us with an explanation lor the high CAD risk of
Tlinidadian Indians. Various studies suggested that the increased risk of Asian Indiar.rs
results from genetic factors (e.g. predisposition of insulin resistance), or altered
enl,ironmental factors (e.g. emigration and urbanisation), or their combination. An as
yet poorly understood cause may be found ir.r the relatior.r between low birth weight and
the risk of insulin resistance and CAD at later life. Ethnicity of Trinidadian newborns is
indeed a significant lactor in birth u'eight, with children from Indian mothers having
lower birtli weights, compared with Africans and Mixed. According to the 'thrifty
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dealing with a (transient) increase of CAD as an outcome of a higher risk for the
development of Syndrome X. The latter may result from a rapid change in
environmental factors (such as an affluent diet and less physical activity) in a metabolic
setting that had been programmed for nutritional thrift during the intrauterine period.
In chapter 3.2, we investigated classical ipid risk factors, apo-E genotypes and other
CAD risk factors of CAD patients in Curagao in a case-control study design. Apo-E
genotype distributions of CAD patients were compared with those of age, race and sex
matched controls and those of newborns. In addition, we studied the association between
apo-E genotypes with lipid indices.
Compared with controls, male CAD patients had higher cholesterol, triglycerides,
LDl-cholesterol, apo-B and decreased HDl-cholesterol and HDl-cholesterol/cholesterol.
Other CAD risk factors were increased fasting glucose and HbAr., decreased creatinine
clearance, and increased prevalences of Lp(a) >500 mgll, renal disease,
hyperhomocysteinaemia, diabetes mellitus type II (DM-ll), positive CAD family history
and cigarette smoking. Male CAD patients had higher plasma cr-tocopherol. Compared
with controls, female CAD patients had higher fasting plasma glucose, HbA1. and DM-ll
prevalence. Predicting factors for CAD development in the whole CAD group were DM-
II, cigarette smoking, and apo-e3/ea nd apo-ea/ea genotypes. The apo-ea allele was
associated with lower HDL- and higher LDl-cholesterol.
This study shows that commonly known lipid risk factors (high total cholesterol,
LDl-cholesterol and triglycerides, and low HDl-cholesterol and HDl-cholesterol/total
cholesterol) and other risk factors (positive family history, cigarette smoking) are involved
in CAD development in Curagao. Most patients were males, confirming male gender as a
CAD risk factor. We conclude that classical atherogenic lipid risk factors and cigarette
smoking are associated with CAD risk in Curaqao. Diabetes mellitus type II may
contribute considerably to CAD development, notably in women. The apo-ea allele,
possibly by induction of a more atherogenic lipid profile, is likely to be a risk factor. There
is a need for local studies on the improvement of diabetic control, reference values of Lp(a)
and homocysteine, apo(a) phenotypes, causes of hyperhomocysteinaemia, and dietary
influences on CAD development in subjects with the apo-ea llele.
Patients with CAD are advised to augment heir dietary polyunsaturated fatty acid (PUFA)
intakes at the expense of saturated fatty acids (SAFA). Linoleic acid (LA) is the
quantitatively most impoftar.rt dietary PUFA in Western countries. In chapter 3.3 we
investigated whether the dietary LA intake of the Curagao CAD patients (see chapter 3.2)
was higher as compared to their controls. For this we measured the plasma cholesterol
ester (CE) fatty acid composition, which reflects the dietary fatty acid composition of the
preceding weeks. By comparing the CE fatty acid compositions of the controls with those
reported in the literature, we tried to identify CAD risk factors that are related to the
Curagao dietary fatty acid composition.
Patients with CAD and controls had minor differences in CE fatty acids. The
groups notably did not differ in CE LA, which suggests that both have the same dietary
PUFA/SAFA ratio. Their CE LA content suggests that the dietary PUFA/SAFA ratio is far
below the recommended value of 1, as issued by the American Hearl Association.
Comparison with data reporled for The Netherlands, Greenland and Crete showed that tl.re
dietary fatty acid composition in Curagao is typically Westem with a high intake of SAFA,
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a low ir.rtake of monounsaturated fatty acids and the consumption of LA as the
predominant PUFA. The small diÍïerence between CE eicosapentaeinoic a id (EPA) and
docosahexaenoic acid (DHA) contents of Curagao and The Netherlands suggests that
intake of EPA and DHA from fish in Curagao is not likely to be very much higher than the
low intake in The Netherlands. Cretans have lower CAD incidence than may be expected
fron.r their n.rajor isk factors. It is explained by their higher dietary intake of oleic acid
(from olive oil) at the expense of LA which leads to a higher dietary a-linolenic/linoleic
acid (ALA/LA) ratio. The low CE ALA/LA ratio in Curagao, as compared with Crete,
points at a low ALA/LA ratio in the diet, which is consistent with the local use of
predominantly com- and sunflower oils.
We conclude that reduction of dietary SAFA, augmentation of fish consurnption,
and an increase of the AL{LA ratio are likely to be of benefit to both primary and
secondary CAD prevention in CuraEao.
Chapter 4: Nutrit ion
Hyperhor.nocysteinaemia is ar.r independent risk fàctor Íbr premature atherosclerosis.
Plasma homocysteine levels are dependent on genetic (mutations in enzymes, involved
in homocysteine metabolism) and nutritional (folic acid, vitamin Be and vitamin 812)
factors. In chapter 4.1 we investigated the effect of a short term supplementation of
vitamin Bo and subsequently folic acid on the fasting plasma homocysteine
concentrations of 103 apparently healthy Dutcl.r volunteers, aged 20-75 years. Plasma
folic acid, vitamin Bt2 and hornocysteine and whole blood vitamin 86 were measured at
baselir.re, and after supplementatior.r with vitamin Br, and folic acid.
Baseline folic acid concentrations of the participants were above the lower limit
of the referer.rce range. Plasma homocysteine was inversely related to plasma folic acid
and vitamin Brz at that moment. Plasma homocysteine did not change after vitamin 86
supplementation and only one participant exhibited a significant plasnra homocysteine
decrease in that period. Plasma homocysteine dropped significantly following folic acid
supplernentation. Tl.rose who exhibited the biggest absolute plasma l.romocysteine
decreases had the lowest initial folic acid concentrations. Forly participants (40%)
exhibited significant plasma hor.nocysteine decreases ir.r that period. Plasma
homocysteir.re was still related to plasma vitamin Btz at the study end, which may be
caused by 19 subjects with vitarnin Bl2 concentrations in the low-normal or below-
nolmal range. We conclude that notably the folic acid status was the cause of not
exhibiting the lowest possible homocysteine concentrations in the present study
population. This may also be true for the vitamin B12 status, though to a lesser extent,
but not for the vitamin 86 status.
Since atherosclerosis risk may increase continuously with increasing plasma
hor.nocysteine, it seems advisable to keep plasma homocysteine levels as low as possible
by augmentation of the folic acid intake. A beneficial effect of lowering plasma
homocysteine on atherosclerosis risk is, however, as yet unproven and should come
lrom randomised prospective interventior.r studies with healthy subjects. It will on the
other l.rand take much time before their results will be available when such studies aim
at hard clinical endpoints. Fortif ication of f lour and cereals with 140 or 350 pgi 100 g
has been estimated to increase folic acid intakes by 160-170 or 280-350 pg/day, which
is likely to cause a 4.8-5.4 o% reduction in mortality from coronary aftery disease in












































not to wait for the outcome of randomised intervention studies, but meanwhile aim at a
folic acid intake that causes no further plasma homocysteine decrease. This intake has
been estimated at 350-400 yt"glday. Since at present only 60Á of the Dutch population has
daily folic acid intakes >400 pg, the above advice translates practically into an
augmented consumption of folic acid rich or folic acid fortified foodstuffs, or the intake
of folic acid supplements.
In chapter 4.2 we used the data of the study in chapter 4.1 to establish a new cut-off
value for plasma folic acid. In addition to fasting plasma homocysteine concentrations,
we present data on plasma homocysteine concentrations 6 h after oral administration of
methionine (oral methionine tolerance test; OMTT).
The diagnosis of subclinical folic acid deficiency is important, since it is
increasingly becoming clear that this condition may contribute to CAD development in
the long run. Clinical chemical reference values are usually determined by calculation
of the 95% confidence interval of data from apparently healthy subjects. Individuals
with subclinical vitamin deficiencies can not be excluded from the reference population
on clinical grounds, because they do not exhibit symptoms that can be related directly to
their suboptimal vitamin status. A solution to the above vicious circle is to define
suboptimal vitamin status on biochemical grounds, i.e. by the measurement of a
vitamin-dependent function (i.e. a functional marker).
In our study, the plasma homocysteine concentration served as a functional
marker to establish the cut-off value of the plasma folic acid concentration. For this, we
investigated at baseline its relation with fasting plasma homocysteine and plasma
homocysteine at 6 h during OMTT, and also its relation with the decline of fasting
homocysteine following 7 days of supplementation with a pharmacological dose of folic
acid. The Íinally selected plasma folic acid cut-off value was defined as the
concentration at, or below, which an individual has a significantly higher chance to
lower its plasma homocysteine following folic acid supplementation, compared with the
chance to exhibit such a decrease when the plasma folic acid concentration exceeds this
value. The results ofthe three approaches uggested a cut-offvalue of 10 nmol/l.
The presently suggested plasma folic acid cut-off value contrasts clearly with our
locally used reference range of 4-30 nmol/1. 'fhis reference range reflects the 95oÁ
confidence interval ofapparently healthy subiects, and it was consequently not surprising
that the newly selected population had values above the lower limit of this range. We now
find that 32 subjects (3 1%) have values below the new cut-off value of 10 runol/I. From
those who had vaiues below 10 nmol/I, 66% significantly decreased their fasting plasma
homocysteine upon folic acid supplementation, whereas this was the case for 28% with
values above 10 nmol/l. Values above 10 nmol/I, therefore, do not necessarily imply that
the lowest homocysteine l vels are always reached.
Since there is compelling, though circumstantial, evidence that low Íblic acid and
high homocysteine are associated with atherosclerosis risk, we advice to adopt plasma
folic acid cut-off values that are based on functional grounds, and not on the 95%
confidence interval ofthe folic acid concentration ofan apparently healthy population.
Oxidation of LDL is considered to play an imporlant role in the pathogenesis of CAD.
The anti-oxidants vitamin E (a-tocopherol) and B-carotene may protect LDL from




and secondary CAD prevention is not consistently found. Adipose tissue serues as
storage site for a-tocopherol and B-carotene. Little is known on the rapidity and extent by
which human adipose tissue accumulates a-tocopherol and B-carotene during
supplementation and to what extent adipose tissue contributes to circulating levels during
fat mobilisation, as occurs during fasting. In chapter 4.3 we investigated the influence of
fasting on the levels of a-tocopherol in plasma, erythrocy'tes and platelets, and on
plasma B-carotene before, during and after oral a-tocopherol and B-carotene
supplernentation. For this, six apparently healthy adults were subjected to 17 h feed-
fasting experiments at various days before, during and after supplementation with a-
tocopherol and B-carotene. We also monitored the kinetics of cx-tocopherol and B-
carotene accumulation in and disappearance from adipose tissue.
Supplementation increased o-tocopherol and p-carotene in all compartments,
except for p-carotene in adipose tissue. Discontinuation caused a rapid return to
baseline, except for adipose tissue o-iocopherol and plasma B-carotene. Fasting caused
linear increases of free fatty acids (reflecting adipose tissue mobilisation), consistent
(but small) increases of plasma c-tocopherol and ir.rconsistent increases of plasma B-
carotene. The different behaviours of a{ocopherol and B-carotene are most probably due
to their different chemical properlies, causing difÍèrent distributior.r among lipoproteins and
consequently different orgar.r distributions and organ accumulation rates. After its entry in
the circulation, the ampliphatic o-tocopherol, located in the surface of chylomicrons, is
likely to become rapidly distributed among a large body surface area, composed of the
surfaces of all plasma lipoproteins, cellular membranes and finally the surfaces of adipose
tissue triglyceride droplets. The highly apolar B-carotene will also enter the circulation in
chylomicrons, but it will be located in the core. Consequently B-caroter.re, like retinol
esters, will predominantly be targeted to the liver via tl.re uptake of chylomicron remnants.
Subsequent secretion of B-carotene via VLDL explains its predominant plasma localisation
in LDL and its prolonged residence in plasma due to its (slow) LDl-receptor mediated
uptake in organs.
We conclude that adipose tissue a-tocopherol and B-carotene contents are likely
to reflect their long term intakes, but the storage pools do not seem able to maintain
high a-tocopherol and B-carotene contents in circulating lipoproteins and cells
following a short-term supplementation. Maintenance of high contents may necessitate
regular  h igh ora l  in takes.
Epidemiological studies show an inverse relation between the intake of long-chain-
polyunsaturated fatty acids of the co3 series (LCPUFATo3; abundant in fish oil) and
CAD risk. In addition, many fish oil supplementation trials suggest beneficial effects on
importar.rt mediators in CAD development. These effects are largely ascribed to EPA
(20:5tr3), which competes with arachidonic acid (AA; 20:4<'t6) for incorporation into
cellular phospholipids, and thereby alters the eicosanoid balance to a state of less
platelet aggregation and less vasoconstriction.
LCPUFA of the o3 and cl6 series derive eitl.rer from the diet or synthesis from
the parent essential fatty acids ALA (18:3o3) and LA (18:2o6). Synthesis occurs by
alternating desaturation and chain elongation reactions, in which the first step, A6-
desaturation, is rate limiting. Some studies with both humans and rats indicated that
administration of y-linolenic acid (GLA; 18:3to6) augments LCPUFATo3 status,
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probably by its ability to stimulate the conversion of ALA to LCPUFAto3 through
augmented A6-desaturation activity. The 'Seven Countries Study' showed that the
Cretan diet is associated with lower CAD mortality rate, despite comparable serum
cholesterol levels. The Cretan diet is characterised by a high consumption of oleic acid
from olive oil, at the expense of LA from sunflower oil, resulting in a high ALNLA
ratio. Beneficial effects of an increased ALA/LA ratio were demonstrated in the 'Lyon
Diet Heart Study'. The intervention comprised adaptation to the Cretan diet, and caused
a 70%o reduction of all cardiac events in patients who recovered from myocardial
infarction. The beneficial effect may derive from many factors, including augmented
LCPUFA<,13 status.
In chapter 4.4 we investigated whether a short term supplementation with low
dose GLA augments the LCPUFAo3 status of 15 apparently healthy adults. Eight of
them took GLA daily during 4 weeks and the remaining 7 took ALA daily to investigate
the influence ofeach ofthese fatty acids separately. In the consecutive 4 weeks all 15
took ALA + GLA. The ALA dose was chosen to reach the same dietary ALA/LA ratio
as used in the Lyon Diet Heart Study. Our results indicate that ALA and GLA
supplementation caused statistically significant increases of ALA and GLA in nearly all
studied compartments, that GLA supplementation caused an increase of dihomo-1-
linolenic acid in all studied compartments, but that the supplements had negligible
effects on the levels of AA, EPA and DHA.
We conclude that LCPUFAo3 status can not be improved by supplementation of
Iow dose GLA, ALA or GLA + ALA. From literature data, it can be concluded that
augmentation of the LCPUFAo3 status by ALA supplementation is poor compared
with fish oil. The discrepancy may be explained by preferential oxidation of ALA, an
inhibitory effect of dietary AA from the omnivorous diet (since AA exens negative
feed-back inhibition on the desaturating enzymes), or by the low dietary ALA/LA ratio.
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